22.84 USD
▲+0.16+2.74%
盘后 22.47 +1.08%
2026-08-03
市值
$1.26B
市盈率
—
EPS
-5.25
股息率
—
52 周区间
14.72 – 34.19
成交量
299.21K
Beta
—
目标价
34.38
52W 低 14.7252W 高 34.19
价格走势
公司简介
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company’s lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225A...